Anti-Lipopolysaccharides IgG

Anti-lipopolysaccharide (LPS) IgG antibodies are immune proteins that target LPS, a component of Gram-negative bacteria. 

Their presence indicates prior exposure to these bacteria and suggests past immune activity, unlike IgM antibodies, which reflect recent exposure. 

Clinically, elevated anti-LPS IgG levels are significant as they correlate with increased permeability of the intestinal and blood-brain barriers, leading to systemic inflammation and autoimmune responses. 

These antibodies are often elevated in patients with inflammatory bowel diseases like Crohn's disease and ulcerative colitis. They also correlate with antibodies against barrier proteins, indicating a higher risk for barrier dysfunction and associated complications. 

Screening for anti-LPS IgG in these patients can help detect early barrier damage, potentially mitigating disease progression and preventing neurological comorbidities.

What are Anti-Lipopolysaccharide IgG Antibodies?

Anti-LPS IgG antibodies are immunoglobulins of the IgG class that specifically target lipopolysaccharides (LPS), which are major components of the outer membrane of Gram-negative bacteria. 

The presence of anti-LPS IgG antibodies suggests that an individual has been previously exposed to Gram-negative bacteria. Unlike IgM antibodies, which indicate recent exposure, IgG antibodies persist longer and reflect past immune activity against these bacteria. [15.]

Anti-LPS IgG antibodies are clinically significant because they indicate increased intestinal and blood-brain barrier permeability, which is linked to systemic inflammation and autoimmunity. [15.] 

Elevated levels of these antibodies are found in patients with IBD, such as Crohn's disease (ASCA-positive) and ulcerative colitis (ANCA-positive). [15.]

The presence of anti-LPS IgG correlates with antibodies against barrier proteins like zonulin, occludin, S100B, and aquaporin-4, suggesting a higher risk for barrier dysfunction and related complications. [15.]

Screening for these antibodies in IBD patients can help detect and prevent early barrier damage, potentially mitigating disease progression and neurological comorbidities.

What are Lipopolysaccharides?

Lipopolysaccharides (LPS), also known as endotoxins, are integral to the outer membrane of Gram-negative bacteria such as Escherichia coli and Salmonella, as well as other pathogens. [3.]

They are pathogen-associated molecular patterns (PAMPs) are conserved molecular structures produced by microorganisms that are recognized by the innate immune system as foreign. [13.]

These molecular patterns enable the immune system to distinguish between self and non-self, initiating appropriate immune responses to combat microbial infections. [13.]

LPS consist of three regions: lipid A, core oligosaccharide, and O-chain. [3.]

LPS interacts with LPS-sensitive cells to produce endogenous mediators like tumor necrosis factor alpha (TNFα), which is crucial for the lethal effects of endotoxin. Macrophages are primary mediators of LPS toxicity, with TNFα being the main lethal agent. [6.]

Chemical Structure and Composition of Lipopolysaccharides [3., 6.]

Lipopolysaccharides are composed of three main parts: lipid A, a core polysaccharide, and an O-specific polysaccharide chain.

Lipid A, embedded in the bacterial outer membrane, is responsible for the molecule's endotoxic effects. It consists of a disaccharide backbone with attached fatty acids, anchoring the LPS to the membrane. 

Lipid A is the most bioactive component, inducing pro-inflammatory cytokines and leading to conditions like septic shock when LPS enters the bloodstream. 

The immune system recognizes Lipid A, initiating an inflammatory response to clear bacterial infections. However, bacterial modifications in LPS, especially Lipid A, help pathogens evade host defenses. [4.]

The core polysaccharide is connected to lipid A and typically contains unusual sugars. 

The O-specific polysaccharide, or O-antigen, extends outward from the bacterium and varies greatly among different bacterial species. This variability in the O-antigen is used for serotyping different strains of bacteria. 

The complex structure of LPS allows it to interact with the immune system, triggering strong inflammatory responses.

What are Lipopolysaccharides Found In?

Lipopolysaccharides (LPS) are found in the outer membrane of Gram-negative bacteria. These molecules play a critical role in maintaining the structural integrity of the bacteria and are key activators of the host immune response.

What Do Lipopolysaccharides Do?: Biological Role and Functions of Lipopolysaccharides [3., 6.]

LPS are essential for the structural integrity of Gram-negative bacteria; they serve as potent immunogenic molecules; and they play a critical role in the pathogenicity and immune interactions of these bacteria.

Structural Role

LPS are integral components of the outer membrane of Gram-negative bacteria, contributing to membrane stability and function.

Immunogenic Properties

LPS are highly immunogenic, eliciting strong immune responses by interacting with the host's immune system. They induce the formation of antibodies specific to different regions of the LPS molecule, such as the O-polysaccharide, core oligosaccharide, and lipid A.

Pathogenicity

LPS are key agents in the pathogenicity of Gram-negative bacteria, playing a significant role in the development of Gram-negative shock. They interact with LPS-sensitive cells to produce endogenous mediators, such as tumor necrosis factor alpha (TNFα), which is crucial for the lethal effects of endotoxins.

Endotoxic Activity

The biological activity of LPS resides primarily in the lipid A region, which is responsible for the toxic effects observed during Gram-negative septic shock. The polysaccharide component, while immunogenic, does not exhibit toxic activity.

Serological Specificity

The O-polysaccharide region of LPS determines the serological specificity of the parent bacterial strain, making it a valuable tool for bacterial identification and classification.

Protective Mechanisms

LPS contribute to the bacterium's ability to evade the host immune system by activating various immune pathways, which can sometimes benefit the host by inducing resistance to infection or acting as adjuvants in immune responses.

Lipopolysaccharides as Pyrogens [11.]

Fever, typically triggered by infections or inflammation, is initiated by the activation of the innate immune system through LPS, which engages the complement cascade and Toll-like receptors. 

This activation leads to the rapid production of prostaglandin E2 (PGE2) and proinflammatory cytokines, primarily involving liver Kupffer cells. 

The pyrogenic signal is then transferred to the brain via neuronal and humoral pathways, resulting in a biphasic febrile response. 

During fever, counterinflammatory factors, known as "endogenous antipyretics," help regulate and limit the fever's intensity and duration. 

The interplay of these pro- and antipyretic signals forms the basis of endotoxic fever.

Health Implications of Lipopolysaccharides

Lipopolysaccharides (LPS) play a critical role in mediating immune responses and are implicated in various health conditions. Their presence and levels in the body can significantly influence the inflammatory process, contributing to both protective and pathological outcomes. 

Role of Lipopolysaccharides (LPS) in Inflammatory Responses [4., 16.]

Lipopolysaccharides (LPS) are critical pathogen-associated molecular patterns (PAMPs) recognized by pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs), triggering immune responses. 

LPS activates both the MyD88-dependent and TRIF-dependent pathways of TLR4, leading to the production of proinflammatory cytokines and type I interferons, essential for detecting and responding to Gram-negative bacterial infections.

LPS also promotes autophagy, aiding in the elimination of intracellular pathogens and damaged organelles by activating pathways involving NF-κB, Beclin 1, and the PI3KC3 complex, thus regulating inflammation

LPS induces chronic low-grade inflammation and metabolic endotoxemia, leading to insulin resistance and metabolic syndrome (MetS). [16.]

LPS, Diabetes, Insulin Resistance, and Metabolic Syndrome

LPS from Gram-negative bacteria enters the bloodstream due to disrupted gut microbiota from a high-fat diet, causing chronic low-grade inflammation and metabolic endotoxemia. [16.]

This leads to insulin resistance and metabolic syndrome (MetS), marked by elevated biomarkers like lipopolysaccharide binding protein (LBP) and C-reactive protein (CRP). 

Addressing MetS involves targeting inflammation and insulin resistance via dietary interventions that improve gut microbiota composition, enhancing gut barrier integrity and reducing LPS levels. [16.]

Key biomarkers for monitoring MetS include LBP, CRP, fasting insulin, and HOMA-IR. [16.]

LPS has also been associated with the progression of nonalcoholic fatty liver disease, NAFLD, due to increased inflammation and its links to metabolic syndrome. [1.]

LPS and Cardiovascular Disease

LPS translocation into the bloodstream, known as metabolic endotoxemia (ME), increases the risk of cardiovascular diseases (CVD) by triggering chronic low-grade inflammation via TLR-4 activation. [10.]

Dysbiosis, or altered intestinal microbiota, increases intestinal permeability, allowing LPS to enter the circulation and contribute to inflammation, plaque instability, and thrombus formation in atherosclerotic arteries. [14.]

Innate immune mechanisms have also been implicated in atherosclerosis and suggest that elevated LPS levels are associated with increased mortality in CAD patients. [8.]

Managing gut permeability through diet and probiotics could mitigate inflammation-related CVD. [8., 10., 14.]

LPS, Gastrointestinal Disease, and Colorectal Cancer

LPS, produced by Gram-negative bacteria, plays a significant role in gut inflammation and inflammatory bowel diseases (IBD) like Crohn's disease and ulcerative colitis. [2.]

It induces chronic inflammation by disrupting gut microbiota and gut-associated lymphoid tissue, leading to "leaky gut" and systemic inflammation. [2.]

LPS activates the NF-κB pathway via TLR4, promoting cytokine cascades that exacerbate inflammation. 

This process is linked to colorectal cancer (CRC) development, particularly in IBD patients. [9.] Targeting LPS and strengthening the gut barrier may offer therapeutic approaches for CRC management. [2., 9.]

LPS and Autoimmune Disease

LPS can enter the bloodstream via intestinal absorption, especially when the gut barrier is compromised, triggering systemic inflammation and contributing to autoimmune diseases. 

LPS is linked to conditions like food allergies and type 1 diabetes. [4.]

For instance, Bacteroides LPS is associated with higher levels of food allergy and anti-insulin antibodies, indicating early immune dysfunction, while Bifidobacterium LPS is linked to a healthy immune system. [4.]

LPS and Neurological Disorders

Lipopolysaccharide (LPS) disrupts host immune homeostasis and intestinal barrier function, leading to gut dysbiosis. 

This results in systemic endotoxemia and contributes to neurodegenerative diseases through oxidative/nitrative stress and inflammation. [7.]

LPS induces chronic systemic inflammation, damaging the blood-brain barrier (BBB), allowing harmful substances to enter the brain, causing neuroinflammation and apoptosis. This process leads to memory impairment and other neurological symptoms. [7.]

LPS triggers inappropriate activation of microglia and astrocytes, affecting mitochondrial function and increasing oxidative/nitrative stress. 

These cellular changes result in clinical symptoms such as cognitive deficits and motor impairments, linking LPS to neuroinflammation and neuronal cell death in diseases like Alzheimer's, Parkinson's, multiple sclerosis, and ALS. [7.]

LPS and Septic Shock

Elevated LPS levels in the bloodstream are associated with sepsis, a life-threatening response to infection causing tissue damage, organ failure, and death. 

Sepsis occurs when the body's response to infection becomes dysregulated, leading to widespread inflammation. 

LPS triggers the release of large amounts of pro-inflammatory cytokines, leading to septic shock characterized by severe hypotension and multiple organ failure. It also activates clotting factors, resulting in disseminated intravascular coagulation, thrombosis, and hemorrhage. [4.]

Lab Testing for Anti-Lipopolysaccharide Antibodies

Overview of Analytical Methods for Lipopolysaccharide Antibodies Detection [4.]

Immunoassays (ELISA) detect LPS antigens or antibodies, with enhanced sandwich ELISA (ENDOLisa) offering improved sensitivity. These are useful for testing adaptive immune responses and monitoring population health risks but are limited by variability in binding and the availability of specific LPS antigens.

Test Information, Sample Collection and Preparation

Blood, serum, or plasma samples are commonly used for anti-LPS antibody detection. The samples must be collected via venipuncture.  

Special preparation is typically not required prior to testing, although certain medications like corticosteroids may affect the results of some testing methods. Individuals with questions about this should consult their ordering provider.

Interpretation of Anti-LPS IgG Test Results

Optimal Levels of Anti-LPS IgG

Optimal levels of Anti-LPS IgG are considered undetectable, or very low.

One company reports LPS ELISA testing results as IgM, IgG, and IgA antibody responses to LPS as part of a panel to assess intestinal barrier integrity.  It reports the following optimal levels as indices, with results greater than 2 standard deviations above the mean being out of reference range: [12.]

Lipopolysaccharides (LPS) IgG: 0.0-2.6

Lipopolysaccharides (LPS) IgA: 0.0-1.8

Lipopolysaccharides (LPS) IgM: 0.0-2.1

Clinical Significance of Elevated Anti-LPS IgG

Elevated levels of anti-LPS IgG antibodies may be clinically significant for several reasons:

Indicator of Increased Permeability [15.]

Elevated anti-LPS IgG antibodies suggest increased permeability of the intestinal and blood-brain barriers. This permeability allows LPS to enter the bloodstream, triggering systemic immune responses. 

Association with Inflammatory Bowel Disease (IBD) [15.]

High levels of anti-LPS IgG antibodies are commonly found in patients with IBD, such as Crohn's disease (ASCA-positive) and ulcerative colitis (ANCA-positive). This elevation correlates with increased immune responses and barrier dysfunction in these conditions.

Systemic Inflammation and Autoimmunity [15.]

The presence of anti-LPS IgG antibodies is linked to systemic inflammation and autoimmune diseases. These antibodies can indicate ongoing immune activation and potential tissue damage due to the inflammatory response to LPS.

Diagnostic and Prognostic Marker [17.]

Anti-LPS IgG antibodies can serve as a diagnostic marker for recent exposure to Gram-negative bacteria. Their levels can also provide prognostic information regarding the severity and progression of diseases associated with barrier dysfunction and systemic inflammation.

Correlation with Other Antibodies [15.]

Elevated anti-LPS IgG levels often correlate with antibodies against barrier proteins like zonulin, occludin, S100B, and aquaporin-4. This suggests a higher risk for barrier dysfunction and related complications, making it a useful marker for early detection and prevention of disease progression.

Related Biomarkers to Test Alongside Anti-Lipopolysaccharide IgG

Testing for anti-lipopolysaccharides (LPS) antibodies provides valuable insights into bacterial infections, intestinal barrier dysfunction and inflammatory responses. 

However, to gain a comprehensive understanding of a patient's health status, it may be beneficial to test for additional biomarkers. 

Biomarkers for Inflammatory Conditions

Inflammation is a critical component of the body’s response to infections and injuries, but chronic inflammation can lead to various health issues. 

C-Reactive Protein (CRP) is a widely used biomarker for inflammation. Produced by the liver, CRP levels rise in response to inflammation. 

Elevated CRP levels, in conjunction with high LPS levels, can indicate a significant inflammatory response, helping diagnose conditions such as sepsis, rheumatoid arthritis, and other inflammatory diseases. 

Measuring CRP provides a quick and reliable assessment of the presence and severity of inflammation.

TNF-alpha and interleukins, particularly interleukin-6 (IL-6) and interleukin-8 (IL-8), are also critical markers of inflammation. These cytokines are produced by immune cells in response to bacterial infections and other inflammatory stimuli. 

High levels of TNF-alpha, IL-6 and IL-8 along with elevated LPS can provide a more detailed picture of the inflammatory processes at play.

These measurements are often used to monitor the effectiveness of anti-inflammatory treatments and to understand the progression of diseases.

Biomarkers for Gut Health

The gut microbiome and intestinal health significantly influence systemic health. Zonulin is a protein that modulates the permeability of tight junctions between cells of the digestive tract. Elevated zonulin levels can indicate increased intestinal permeability, often referred to as "leaky gut." [5.]

This condition allows LPS and other bacterial components to enter the bloodstream, triggering systemic inflammation. Testing for zonulin can help identify issues with gut barrier function, providing context for elevated LPS levels and associated inflammatory responses. [5.]

Calprotectin is another biomarker relevant to gut health. It is a protein found in neutrophils, and elevated levels in stool indicate inflammation in the gastrointestinal tract. 

High calprotectin levels can be associated with inflammatory bowel disease (IBD), such as Crohn’s disease and ulcerative colitis. [2.]

Measuring calprotectin alongside LPS can help differentiate between different causes of gastrointestinal symptoms and provide a more comprehensive assessment of gut health. [2.]

Order LPS Testing

Click here to compare testing options and order testing for LPS.

Click here to explore the test for antibodies against LPS referenced above.